ArticleChinese medicine2026
Rhapontigenin alleviates cellular senescence and physiological aging by upregulating sirt1 and promoting autophagy.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRT1 in Senescence: Mitochondria and Immune Crosstalk.Biology · 2026Review
- Emodin alleviates radiation-induced pulmonary fibrosis by targeting cellular senescence via the mtDNA-cGAS-STING axis.Biogerontology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAging is characterized by cellular senescence, inflammation, and physiological decline. Currently available antiaging therapies often have limitations due to their toxicity and off-target effects. However, natural compounds derived from Chinese herbal medicine, such as Rhapontigenin (Rhap), have shown potential as safer antiaging agents. PURPOSE: This study aimed to evaluate the potential of Rhap to be used as an antiaging agent by investigating its effects on cellular senescence, physical function, immune modulation, and autophagy in both in vitro and in vivo aging models.
methodsNIH3T3 and IMR90 cells were subjected to oxidative or genotoxic stress to induce senescence and then treated with Rhap. Senescence markers, cell viability, and autophagy-related protein levels were assessed. Aged mice were treated with Rhap for 8 weeks, and physical performance, immune modulation, and organ health were evaluated. Mechanistic studies were conducted to determine the role of Sirt1 in mediating the effects of Rhap.
resultsRhap treatment significantly reduced cellular senescence marker (p16 and p21) levels and senescence-associated β-galactosidase (SA-β-Gal) activity in stressed cells. In aged mice, Rhap improved physical performance, such as grip strength and motor coordination, and reduced depressive-like behaviors. Rhap also decreased liver senescence, lipid accumulation, and fibrosis and increased immune function by reducing proinflammatory cytokine production and enhancing T-cell homeostasis. Mechanistically, Rhap upregulated Sirt1 and promoted autophagy, both of which contributed to its antiaging effects. Sirt1 knockdown attenuated the effects of Rhap on autophagy and senescence, indicating the importance of Sirt1 in mediating these beneficial effects.
conclusionRhap is a promising candidate for mitigating age-related cellular and physiological decline by reducing cellular senescence, promoting autophagy, and modulating immune function. However, further work is needed to fully elucidate the precise molecular mechanisms of Rhap's action and its pharmacokinetic profile to assess its translational potential in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.